Nemaura Medical's Board Of Directors And Management Team Have Made The Strategic Decision To Accept Nasdaq's Determination To Delist Nemaura Medical And Move To The OTC Markets
Portfolio Pulse from Benzinga Newsdesk
Nemaura Medical's Board and Management have decided to accept Nasdaq's decision to delist the company. They plan to transition to trading on the OTC Markets.

January 03, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nemaura Medical is set to be delisted from Nasdaq and will move to the OTC Markets following a strategic decision by its Board and Management.
Delisting from a major exchange like Nasdaq typically reflects negatively on a company's market perception, potentially leading to reduced visibility, liquidity, and investor confidence. The move to OTC Markets is often seen as a step down, which could negatively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100